489 related articles for article (PubMed ID: 32743759)
1. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
3. YTHDF1 Promotes Cyclin B1 Translation through m
Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
[TBL] [Abstract][Full Text] [Related]
4. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
Wu C; Rao X; Lin W
Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
[TBL] [Abstract][Full Text] [Related]
5. Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.
Tian HX; Chen ZH; Jie GL; Wang Z; Yan HH; Wu SP; Zhang SL; Lu DX; Zhang XC; Wu YL
Cancer Med; 2023 Jan; 12(1):396-406. PubMed ID: 35702826
[TBL] [Abstract][Full Text] [Related]
6. A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with
Fu J; Li Y; Li C; Tong Y; Li M; Cang S
Transl Cancer Res; 2021 Sep; 10(9):3963-3978. PubMed ID: 35116695
[TBL] [Abstract][Full Text] [Related]
7. Analysis of genes associated with prognosis of lung adenocarcinoma based on GEO and TCGA databases.
Yu Y; Tian X
Medicine (Baltimore); 2020 May; 99(19):e20183. PubMed ID: 32384511
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.
Liu DH; Zhao ZR; Lin YB; Zhou WJ; Hou JY; Ye ZH; Long H
Ann Surg Oncol; 2019 Jun; 26(6):1934-1941. PubMed ID: 30820786
[TBL] [Abstract][Full Text] [Related]
9. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer.
Stockhammer P; Grant M; Wurtz A; Foggetti G; Expósito F; Gu J; Zhao H; Choi J; Chung S; Li F; Walther Z; Dietz J; Duffield E; Gettinger S; Politi K; Goldberg SB
J Thorac Oncol; 2024 Feb; 19(2):240-251. PubMed ID: 37806385
[TBL] [Abstract][Full Text] [Related]
10. Genomic landscape and prognosis of patients with
Fan Z; Zhang Q; Feng L; Wang L; Zhou X; Han J; Li D; Liu J; Zhang X; Zuo J; Zou X; Cai Y; Sun Y; Wang Y
Ann Transl Med; 2022 Feb; 10(4):188. PubMed ID: 35280362
[TBL] [Abstract][Full Text] [Related]
11. Effects of concurrent TP53 mutations on the efficacy and prognosis of targeted therapy for advanced EGFR mutant lung adenocarcinoma.
Qian H; Hou C; Zhang Y; Ji S; Zhong C; Li J; Zhang Q; Huang J; Li C; ChengJi
Cancer Genet; 2023 Nov; 278-279():62-70. PubMed ID: 37672936
[TBL] [Abstract][Full Text] [Related]
12. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.
Li H; Yang L; Wang Y; Wang L; Chen G; Zhang L; Wang D
BMC Bioinformatics; 2023 Apr; 24(1):155. PubMed ID: 37072703
[TBL] [Abstract][Full Text] [Related]
13. The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis.
Zhang R; Tian P; Chen B; Wang T; Li W
Postgrad Med; 2019 Apr; 131(3):199-206. PubMed ID: 30798634
[TBL] [Abstract][Full Text] [Related]
14. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of tumor mutation burden in
Jiao XD; He X; Qin BD; Liu K; Wu Y; Liu J; Hou T; Zang YS
J Thorac Dis; 2019 Nov; 11(11):4507-4515. PubMed ID: 31903239
[TBL] [Abstract][Full Text] [Related]
16. The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.
Mizutani K; Guo X; Shioya A; Zhang J; Zheng J; Kurose N; Ishibashi H; Motono N; Uramoto H; Yamada S
Int J Med Sci; 2019; 16(9):1199-1206. PubMed ID: 31588184
[No Abstract] [Full Text] [Related]
17. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
18. Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.
Zeng D; Hu Z; Yi Y; Valeria B; Shan G; Chen Z; Zhan C; Lin M; Lin Z; Wang Q
BMC Pulm Med; 2021 Oct; 21(1):316. PubMed ID: 34635074
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
Jiao XD; Qin BD; You P; Cai J; Zang YS
Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
[TBL] [Abstract][Full Text] [Related]
20. Potential Impacts of
Lee KL; Lai TC; Wang YC; Shih PC; Yang YC; Tsao TC; Liu TC; Wen YC; Chang LC; Yang SF; Chien MH
Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33802737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]